About Kevin Rakin
Kevin Rakin is a director of Allyx Therapeutics, which is developing oral drugs for Alzheimer’s and other neurodegenerative diseases. At Elutia, a regenerative medicine company he helped start, he serves as chairman. He co-founded HighCape Partners, an investment fund, and has been a general partner there since 2013. Since June 2020, he has also served as chief executive officer of HighCape Capital Acquisition Corp., a publicly traded HighCape affiliate.
Rakin previously co-founded Genaissance Pharmaceuticals and served as president and chief executive officer until its 2005 merger with Clinical Data. He currently serves on boards including Oramed Pharmaceuticals, Convexity Scientific and Nyxoah. His earlier board work includes Histogenics, TELA Bio and Cheetah Medical. Rakin holds an MBA from Columbia University and B.Com and B.Com Honors degrees from the University of Cape Town.
Experience
This experience comes from official bios, from Kevin Rakin's profile and from SEC filings. For roles taken from filings, the years are when the filings name Kevin Rakin in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people Kevin Rakin works with at each company, as listed on that company's latest Form D.
